NDAIRRIGATIONSOLUTIONPriority Review
Approved
Oct 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
RENACIDIN (citric acid, gluconolactone and magnesium carbonate) by United Therapeutics is acidifying activity [moa]. First approved in 1990.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENACIDIN is a urological irrigation solution containing citric acid, gluconolactone, and magnesium carbonate that dissolves calculi (kidney stones and struvite deposits) through acidifying activity. It is administered via irrigation directly into the urinary tract to prevent stone formation and manage existing calculi in patients with recurrent or catheter-associated urinary tract stones.
$3.0MPart D
LOE ApproachingThis niche, mature product serves a specialized urological population with modest Medicare spending; the approaching LOE suggests the brand team is small and focused on retention rather than expansion.
Mechanism of Action
Acidifying Activity
Pharmacologic Class:
Calculi Dissolution Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENACIDIN offers limited career growth potential given its niche indication, mature lifecycle, and approaching LOE; positions are primarily defensive and focused on protecting existing market share in a specialized urology segment. This product is best suited for early-career professionals seeking hands-on experience in a stable, lower-volume specialty market or those nearing career transition.
Brand Manager
Worked on RENACIDIN at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.